Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
07 2월 2025 - 6:30AM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
products for serious rare and ultrarare genetic diseases, today
announced that it will host a conference call at 5:00 p.m. ET on
Thursday, February 13, 2025, to discuss its financial results and
corporate update for the quarter and the year ending December 31,
2024.
The live and replayed webcast of the call will be available
through the company’s website at
https://ir.ultragenyx.com/events-presentations. The replay of the
call will be available for three months.
About Ultragenyx Pharmaceutical Inc.Ultragenyx
is a biopharmaceutical company committed to bringing novel products
to patients for the treatment of serious rare and ultrarare genetic
diseases. The company has built a diverse portfolio of approved
therapies and product candidates aimed at addressing diseases with
high unmet medical need and clear biology for treatment, for which
there are typically no approved therapies treating the underlying
disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at: www.ultragenyx.com.
Contact Ultragenyx
InvestorsJoshua Higa(415) 475-6370ir@ultragenyx.com
MediaCarolyn Wang(415) 225-5050media@ultragenyx.com
Ultragenyx Pharmaceutical (NASDAQ:RARE)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Ultragenyx Pharmaceutical (NASDAQ:RARE)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025